IMMOXYGENE
ActiveSummary
IMMOXYGENE has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €198,047 and a net result of €42,330. Equity is growing by about 43% per year across the filed financial years. Its solvency ranks better than 77% of 17,042 sector peers (NACE 68, financial year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Sauf modification langue selon règles emploi langues, Région wallonne” (deed in French)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Durée déterminée ou indéterminée, totalité des pouvoirs d’administration” (deed in French)
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
- Share issue ruleHow and by whom new shares can be issued.
- “Articles 5:128 et suivants du Code des sociétés et des associations” (deed in French)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- First Monday of June at 16:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Dissolution société, un ou plusieurs liquidateurs désignés par assemblée générale” (deed in French)